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Cancer represents a novel homeostatic challenge to the host system. How the brain senses and responds to
changes in peripheral physiology elicited by tumor growth is a largely untapped area of research. This is espe-
cially relevant given the widespread prevalence of systemic problems that people with various types of cancer
experience. These include disruptions in sleep/wake cycles, cognitive function, depression, and changes in
appetite/food intake, among others. Critically, many of these problems are evident prior to diagnosis, indicating
that their etiology is potentially distinct from the effects of cancer treatment or the stress of a cancer diagnosis.
Psychoneuroimmunology (PNI) is well equipped to tackle these types of problems, as it uses approaches from
multiple disciplines to understand how specific stimuli (endogenous and environmental) are transduced into
neural, endocrine, and immune signals that ultimately regulate health and behavior. In this article, I first provide
a brief historical perspective of cancer and PNI, introduce the idea of cancer as a systemic homeostatic challenge,
and provide examples from preclinical literature supporting this hypothesis. Given the rise of advanced tools in
neuroscience (e.g., calcium imaging), we can now monitor and manipulate genetically defined neural circuits over
the extended time scales necessary to disentangle distal communication between peripheral tumors and the brain.1. Introduction
Cancer research and psychoneuroimmunology (PNI; i.e., a scientific
discipline focused on interactions among the mind, nervous system, and
immune system) have been intertwined since PNI's inception. In 1975,
for instance, Ader & Cohen (who coined the term ‘psychoneuroimmu-
nology’) used cyclophosphamide, a widely prescribed and immunosup-
pressive chemotherapeutic agent, as an unconditioned stimulus (US) in
their demonstration of behavioral conditioning of the immune response
in rats (R and N, 1975). Conditioned immunosuppression was subse-
quently demonstrated in cancer patients undergoing chemotherapy,
where blood samples taken several days before scheduled treatment
showed greater lymphocyte proliferative capacity when compared to
samples drawn just prior to treatment (Bovbjerg et al., 1990). Around the
same time, Besedovsky & colleagues demonstrated that the presence of
neoplastic cells, either transplanted or autochthonous, could induce
diverse changes in rat plasma endocrine profiles, a process that occurred
before the tumors became palpable and when rats had no overt signs of
disease (Besedovsky et al., 1985). Importantly, these endocrine changes
were not observed upon injection of syngeneic non-cancer cells (e.g.,
hepatocytes). Studies such as these highlight potential pathways by
which the brain can maladaptively regulate peripheral physiology (e.g.,
via modulating the immune response to chemotherapy), and how cancerSeptember 2021; Accepted 17 S
evier Inc. This is an open access ain the body can disrupt systemic (e.g., endocrine) signals sensed by the
brain (Spiegel, 2012; Sloan and Walker, 2019; Gillis et al., 2021).
We now know that tumors must adjust the physiology of their local
environment in order to evade immune destruction and meet metabolic
demands for growth and proliferation. This positions the host system as a
major selective factor in the evolution of cancer (Basanta and Anderson,
2017). Mutant cells that are unable to break free of local homeostatic
control mechanisms will be unable to form tumors. Cells that break past
these barriers to the point that they are clinically relevant undergo a
process of clonal evolution (Greaves and Maley, 2012), where the initial
cell adapts to its environment, remodels it, and diversifies in a process
promoting intratumor heterogeneity (ITH) (Gay et al., 2016). Competi-
tion between cancer cells (clonal interference) and with cells in the
microenvironment leads to highly diverse tumors that are exquisitely
adapted to their local niche. During cancer progression, interactions at
the local level likely propagate to the entire host system, potentially
resulting in adverse outcomes and ultimately, death (Vasquez and Bor-
niger, 2020; Mu et al., 2018; Lee et al., 2014). It follows that approaches
aiming to adaptively bolster homeostatic defenses against an evolving
tumor may augment anti-cancer therapies (Gatenby et al., 2009).
In recent years, an appreciation of the complex interplay between the
host system and cancer development has expanded further into the realm
of the entire organism, with specific emphasis on the liver (Masri et al.,eptember 2021
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et al., 2010; Borniger et al., 2018; Dieterich and Bikfalvi, 2020; Burfeind
et al., 2020a; Olson and Marks, 2019). Here, I use sleep disruption as an
exemplar of the types of systemic problems cancer patients endure. I
discuss evidence frommy prior work on systemic and neurological effects
of cancer development and the potential mechanisms underlying these
problems. I do this to highlight the brain's role in sensing, integrating,
and regulating cancer-induced changes in physiology. I further empha-
size the types of questions that cancer models can help to address in PNI
research.
2. Behavioral co-morbidities in people with cancer
Patients with cancer frequently experience systemic problems that are
likely secondary to the primary tumor formation itself. These include
disorders of physiological and behavioral homeostasis, including dis-
rupted sleep, fatigue, and changes in appetite and food intake resulting in
reorganization of systemic metabolism (Vasquez and Borniger, 2020;
Flint et al., 2016; Baracos et al., 2018). These problems can be debili-
tating. For example, sleep disruption is strongly predictive of subsequent
breast cancer mortality and patient quality of life, even when controlling
for covariates like cortisol concentrations, hormone receptor expression,
age, depression, cancer treatment, and metastatic spread (Palesh et al.,
2014; Trudel-Fitzgerald et al., 2017). Up to 90% of breast cancer patients
will experience chronic sleep disruption and fatigue following a cancer
diagnosis, continuing through surgery, treatment, recovery, and remis-
sion (Budhrani et al., 2015). This phenomenon is also evident in other
cancer patient populations, including those with lung (Masri et al., 2016;
Vena et al., 2006) and colorectal cancer (Innominato et al., 2015),
(Mogavero et al., 2021), (Costa et al., 2014), (Spiegel, 2012), (Spiegel
et al., 1989).
There are two fundamental reasons why we lack a deep mechanistic
understanding of these problems. The first is that due to the large het-
erogeneity of cancer types, treatment regimens, patient populations, and
lifestyle factors that influence the host system, unraveling bidirectional
communication between tumors in the periphery and the brain has
remained challenging. The second is due to the limited interactions that
occur between neuroscientists, cancer researchers, and clinicians, each of
whom use specialized language in their respective fields. In recent years,
however, an appreciation of the impact co-morbid cancer symptoms
(e.g., sleep disruption) have on patients has galvanized researchers to
work at the intersection of these fields (Monje et al., 2020). This has
yielded significant research on how psychological stress, circadian/sleep
disruption, or stimulation of specific areas of the brain influences distal
cancer processes in the periphery (Ben-Shaanan et al., 2018; Thaker
et al., 2006; Filipski et al., 2003; Hakim et al., 2014). However, studies on
how non-CNS tumors may reciprocally influence brain function are
scarce (Mampay, Flint, Sheridan). I believe this represents a major op-
portunity for psychoneuroimmunology, a discipline comfortable with
questions that span multiple organ systems and large temporal scales.
3. Cancer as a homeostatic challenge
The PNI perspective allows us to ‘zoom out’ and think about
neoplastic growth as a threat to the entire host system (i.e., as a ho-
meostatic challenge). For as long as we have recorded our thoughts and
observations, humans have been fascinated by a seeming paradox in
nature: that organisms, which are composed of primarily soft and deli-
cate material, are able to survive and thrive in a dynamic and harsh
environment. This observation led Walter Cannon to develop the concept
of ‘homeostasis’ (in the early 1900s), which forms the foundation of our
understanding of how we interact with the environment in the most
literal sense. The French physiologist, Charles Richet, emphasized this
critical observation in 1900 (Richet, 1900):2
“The living being is stable, …It must be so in order not to be destroyed,
dissolved or disintegrated by the colossal forces, often adverse, which
surround it. By an apparent contradiction it maintains its stability only if it
is excitable and capable of modifying itself according to external stimuli
and adjusting its response to the stimulation. In a sense it is stable because it
is modifiable—the slight instability is the necessary condition for the true
stability of the organism.” - From Walter Cannon's “Wisdom of the
Body”, 1939 (Cannon, 1939)
We now know that the brain plays an essential role in maintaining
homeostasis in physiology and behavior. In response to (or in anticipa-
tion of) endogenous or environmental stimulation, it integrates salient
cues (e.g., change in blood glucose (Burdakov et al., 2006; Burdakov
et al., 2013), bright lights (Rossi et al., 1996), loud sounds (Kayser et al.,
2005)) and exerts influence on distal tissues via both humoral and neural
pathways in an attempt to re-establish systemic stability (Kalsbeek et al.,
2010; Dunn, 2007). Additionally, the brain also directs adaptive changes
in behavior that function to putatively facilitate the return to homeostasis
(e.g., shivering (Thornhill and Halvorson, 1994), food seeking (Car-
us-Cadavieco et al., 2017; Betley et al., 2013), sleeping (Kilduff, 2011;
Morairty et al., 2013)). Importantly, failure to restore physiological
processes to their homeostatic range of functioning for extended periods
can have deleterious consequences for the entire organism, including the
development of chronic disease and ultimately, death (Beutler et al.,
2017; Tan et al., 2016; Vaccaro et al., 2020). Cannon emphasizes the role
of internal factors in challenging homeostasis: “External conditions, how-
ever, are not the only factors which affect the internal environment. The ac-
tivity of the body itself may upset homeostasis; and, if not guarded against,
profound disorders may result.” (Cannon, 1939)
I emphasize these points as cancer disrupts numerous internal factors
that the brain regulates to maintain homeostasis. For example, leptin, an
adipokine hormone that is primarily produced by white adipose tissue,
acts centrally within the hypothalamus to inhibit food intake and regu-
late energy balance (Li, 2011). Within the hypothalamus, arcuate
pro-opiomelanocortin (POMC)-expressing neurons are major targets for
leptin's action. They project to the dorsomedial nucleus, paraventricular
nucleus, and lateral hypothalamus in a circuit that transduces the
adipocyte-derived signal into a neural code (Millington, 2007).
Numerous studies have found altered leptin signaling directly in tumors
and (more broadly) in the systemic circulation of cancer patients.
Overexpression of both leptin and its long-form receptor (LepRb) have
been noted in multiple cancers, including breast, colorectal, liver, and
thyroid cancer (Ishikawa et al., 2004; Han et al., 2005; Koda et al., 2007;
Rajesh and Sarkar, 2021). These findings have led to the development of
several candidate therapeutics targeting leptin receptor signaling in
cancer (Otvos and Surmacz, 2011). It follows that in order for these
therapies to be successful, we need to understand how dysregulated
leptin signaling in cancer interacts with normal hypothalamic circuitry
regulating its function throughout the body.
Another major class of molecules disrupted by cancer are messaging
signals of the immune system: cytokines and chemokines. For example,
interleukin-6, a pleiotropic cytokine that acts on many target tissues
throughout the body and brain is frequently dysregulated in cancer
(Knüpfer and Preiss, 2010; Salgado et al., 2003; Kumari et al., 2016). In
‘triple-negative’ breast cancer, tumor cells can secrete IL-6 directly or in
tandem with stromal cells to promote cancer cell dissemination in a
CCL5/CCR5 dependent manner (Lee et al., 2014). IL-6 can act via its
classical signaling pathway or via the soluble IL-6 receptor (i.e., trans--
signaling) to influence the activity of distal organs, including the brain
(Eskilsson et al., 2014; Timper et al., 2017). How CNS-relevant IL-6
signaling becomes disrupted during cancer progression, and whether this
relates to the development of maladaptive behavioral phenotypes (indi-
cating a potential breakdown in homeostasis) remains undefined.
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I will use an example from my prior work on sleep in cancer to
illustrate how tumors in the periphery may influence the function of the
brain from a distance. There is an assumption that disrupted sleep in
cancer is secondary to the stress of a cancer diagnosis or the result of
chemotherapy-induced inflammation (Bower and Lamkin, 2013; Bower
et al., 2011; Borniger et al., 2015). These factors likely play a role;
however, this view neglects the role the cancer itself may play in regu-
lating sleep. This is important, as patients frequently experience sleep
problems prior to their cancer diagnosis (Phipps Amanda et al.). I
emphasize this as the interactions I detail below are independent from
the large literature surrounding the effect of sleep/circadian disruption
on cancer progression (Filipski et al., 2003; Hakim et al., 2014; Khalyfa
et al., 2016; Blask et al., 2005; Haus and Smolensky, 1016), an area
which is too broad to address adequately here.
We were first to describe a mechanism for non-metastatic breast
cancer-induced sleep and metabolic disruption (Borniger et al., 2018).
We characterized how sleep changes in a model of non-metastatic breast
cancer (67NR syngeneic mammary tumor cells) using electro-
encephalography/electromyography (EEG/EMG) biotelemetry. It was
important to begin by using a non-metastatic model, as we didn't want
the cancer cells themselves to travel to the brain, lungs, or other sites that
may independently influence sleep. This restricted the role the cancer
could have on the brain to direct interactions with local nerves, or via
secreted factors produced by cells within the tumor (i.e., cancer
cells þ stroma). Throughout the course of cancer progression,
tumor-bearing mice reduced their locomotor activity and spent more
time asleep during their active phase, indicating fatigue. Further, sleep
the mice were getting was fragmented and of low quality. The effect of
cancer on sleep was the strongest in the last few days of cancer pro-
gression (i.e., before endpoint criteria reached), so we focused on this
timeframe when searching for a causal mechanism. Importantly, these
aspects of sleep disruption are similar to those observed in patients with
breast cancer (Innominato et al., 2016).
The obvious next step was to identify the neuronal substrate(s)
driving sleep disruption. The hypothalamus is essential for normal sleep
and wakefulness (Saper and Lowell, 2014) and discrete populations of
neurons have been delineated based on their unique gene expression
signatures, projection patterns, and/or developmental trajectory (Mick-
elsen et al., 2019; Bonnavion et al., 2016). In 1998, two groups published
their findings describing a new group of neuropeptides exclusively
expressed in the hypothalamus. Because of its anatomical location and
similarity to the gut hormone secretin, the first group named these
neuropeptides the ‘hypocretins’ (Lecea et al., 1998). The other team
identified (unknowingly) the same neuropeptides via ligand screening
against a library of orphan G-protein coupled receptors (GPCRs). When
they infused these neuropeptides into the rat brain, they observed
increased feeding behavior, leading them to name them the ‘orexins’
after the Greek word for appetite (orexis) (Sakurai et al., 1998).
These hypothalamic neurons are essential for the stability of wake-
fulness. Genetic ablation of hypocretin/orexin neurons or their neuro-
transmitter content results in the debilitating disorder narcolepsy
(Chemelli et al., 1999; Hara et al., 2001; Crocker et al., 2005), which is
characterized by aberrant transitions between arousal states. As we
observed sleep fragmentation in response to breast cancer, we examined
whether different populations of hypothalamic neurons were differen-
tially active in tumor-bearing mice. We systematically examined imme-
diate early gene expression (cFos) across the entire hypothalamus and
found selective increases in hypocretin/orexin neuronal activity in
tumor-bearing mice, without similar changes in co-mingled neurons that
express melanin-concentrating hormone (MCH). When we examined the
hypothalamus as a whole, there was no net increased in cFos expression
between groups, suggesting that there was a specific effect of cancer on
hypocretin/orexin neurons.3
How does breast cancer distally alter the activity of these neurons in
the hypothalamus? Hypocretin/orexin neurons are positioned as major
systemic integrators, adjusting arousal in response to changes in meta-
bolic state (Adamantidis and de Lecea, 2009; Borniger and de Lecea,
2019; Tyree et al., 2018). They express receptors for many systemic cues
disrupted during cancer progression, including glucose, leptin, ghrelin,
and insulin, among others. Tumor-bearingmice were hyperglycemic, and
this was further associated with an upregulation of liver glucose pro-
duction and impairments in insulin signaling (Borniger et al., 2018).
Simultaneously, tumor-bearing animals showed increased sensitivity to
the ‘hunger hormone’ acyl-ghrelin and reduced circulating concentra-
tions of the ‘satiety’ hormone leptin. These signals converge on hypo-
cretin/orexin neurons to increase their net activity, putatively promoting
arousal and disrupted sleep. To test this idea, we used an orally available
dual hypocretin/orexin receptor antagonist, Almorexant (ALX). Repeated
administrations of ALX promoted deep, restorative sleep in
tumor-bearing mice. More interestingly, blocking hypocretin/orexin
signaling also attenuated hyperglycemia and normalized the expression
of several metabolic genes in the liver.
Why would blocking the activity of neurons in the hypothalamus alter
systemic glucose metabolism? Pioneering studies demonstrated that
hypocretin/orexin neurons innervate diverse sympathetic outflow nuclei
in the brainstem (Geerling et al., 2003; Peyron et al., 1998). Additionally,
these neurons promote liver glucose production and elevations in
circulating glucose via the sympathetic nervous system (Yi et al., 2009).
Therefore, we hypothesized that blocking brain-to-body communication
(i.e., via sympathetic denervation) would prevent cancer-induced hy-
perglycemia and liver dysfunction. To test this idea, we administered the
neurotoxin 6-OHDA, which selectively destroys sympathetic noradren-
ergic nerve terminals and does not cross the blood brain barrier, to mice
with and without tumors. In support of our hypothesis, we found that
sympathetic denervation completely attenuated liver dysfunction in
tumor-bearing mice, which was further reflected in reduced circulating
glucose concentrations. Together, these studies provide evidence sup-
porting the idea that non-metastatic cancer indirectly alters the activity
of hypothalamic neurons controlling arousal and systemic metabolism,
the latter via the sympathetic nervous system. This suggests that dele-
terious consequences often associated with cancer (sleep disruption and
metabolic dysregulation) may develop as a result of aberrant homeostatic
responses to cancer-induced changes in physiology.
5. Future work and outstanding questions
Studies such as the one I described above provide hints to the po-
tential breadth of cancer's influence on the brain. Going forward, I
believe cancer can be applied as a ‘bottom-up’ tool to address
outstanding questions in psychoneuroimmunology. The use of autoch-
thonous, syngeneic, and xenograft models allows for elegant experi-
mental designs that can control for tumor immunogenicity, host
genotype, and local tissue interactions that may all differentially influ-
ence the brain. Additionally, these can be combined with behavioral
assays over long time scales (weeks to months), which allow for the
careful charting of cancer's influence on the brain throughout tumor
initiation, progression, and metastatic spread. Further use of optical tools
(e.g., genetically encoded calcium indicators; GECIs (Tian et al., 2012))
permits longitudinal monitoring or manipulation of discrete neuronal
populations in freely moving mice with or without tumors. Neuroscien-
tists are additionally familiar with tract tracing techniques to map neural
circuitry, usually between different brain regions or nuclei. Several of
these tools are amenable for mapping brain-to-body circuits, such as
pseudorabies viral vectors, which travel polysynaptically in the retro-
grade direction from the injection site to label all neurons in a circuit
chain (Arriaga et al., 2015; Smith et al., 2000). Techniques such as these
can reveal multi-synaptic innervation patterns for tumors in the body and
investigation of how these differ from normal, adjacent tissue. In vitro
techniques are also critical for reducing the complexity of biological
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neuron/cancer co-cultures are now possible while keeping each cell type
in their own separated compartments, a technique that was recently used
to reveal a role for sensory nerves in providing the amino acid serine to
pancreatic tumors (Banh et al., 2020). Recent advances in immunophe-
notyping (e.g., mass cytometry (Spitzer and Nolan, 2016; Keren et al.,
2019)), RNA-sequencing (Hwang et al., 2018), and imaging (e.g., Deep
Learning-enabled Metastasis Analysis in Cleared Tissue; DeepMACT (Pan
et al., 2019)) allow for causal relationships between tumor phenotype,
host response, and brain activity to be distinguished.
These strategies can be used to address several outstanding questions
regarding cancer-brain crosstalk:
- What brain areas sense and integrate cancer-derived signals?
- How do these dynamics change over the course of cancer
progression?
- When and how do cancer-induced changes in physiology reach
conscious awareness (e.g., nausea, pain, fatigue)?
- How do cancer treatments alter these pathways?
Further, collaborations with computational scientists will be invalu-
able in developing models of cancer-associated physiological/behavioral
disruption which can then be empirically tested. Additionally, under-
standing how tumor-derived signals alter non-neuronal cells within the
CNS (e.g., glia, endothelial cells) is an area that requires significant work
(Burfeind et al., 2020b), although some progress has been made in the
peripheral nervous system (Stierli et al., 2019). Together, our evolving
concept of cancer as a unique challenge to the host system, combined
with recent technological advances in experimental tools, yields a fertile
research area for further work. I believe that this integrative approach
will provide the greatest benefit to those suffering from cancer.
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